| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Wesley C Van Voorhis | Q29838907 |
| P2093 | author name string | Ekachai Jenwitheesuk | |
| Ram Samudrala | |||
| Jeremy A Horst | |||
| Kasey L Rivas | |||
| P2860 | cites work | PIRSpred: a web server for reliable HIV-1 protein-inhibitor resistance/susceptibility prediction. | Q53861591 |
| Prediction of HIV-1 protease inhibitor resistance using a protein-inhibitor flexible docking approach. | Q53867047 | ||
| Identification of potential multitarget antimalarial drugs. | Q55041259 | ||
| SCOP: a Structural Classification of Proteins database | Q56039751 | ||
| Rapid selection of drug-resistant HIV-1 during the first months of suppressive ART in treatment-naive patients | Q59694926 | ||
| TOXNET: the National Library of Medicine's toxicology database | Q71550343 | ||
| New developments in anti-HIV chemotherapy | Q74526095 | ||
| Limitations of a simplification antiretroviral strategy for HIV-infected patients with decreasing adherence to a protease inhibitor regimen | Q79300709 | ||
| Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway | Q79856252 | ||
| Improved accuracy of HIV-1 genotypic susceptibility interpretation using a consensus approach | Q80465045 | ||
| Virtual screening: a real screening complement to high-throughput screening | Q94074402 | ||
| Structural evolution of the protein kinase-like superfamily | Q21145694 | ||
| Improved prediction of HIV-1 protease-inhibitor binding energies by molecular dynamics simulations | Q24794072 | ||
| The TIM-barrel fold: a versatile framework for efficient enzymes | Q28205462 | ||
| Comparison of super-secondary structures in proteins | Q28245103 | ||
| Current development of mTOR inhibitors as anticancer agents | Q28255366 | ||
| Can we rationally design promiscuous drugs? | Q28294268 | ||
| Inhibition of Human Immunodeficiency Virus Infectivity by Chloroquine | Q28323345 | ||
| An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk] [1,4]benzodiazepin-2 (1H)-one and -thione derivatives | Q28323682 | ||
| Identification of novel parasitic cysteine protease inhibitors using virtual screening. 1. The ChemBridge database | Q45179943 | ||
| Kernels for small molecules and the prediction of mutagenicity, toxicity and anti-cancer activity. | Q46364876 | ||
| A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group | Q46778238 | ||
| Identification of novel parasitic cysteine protease inhibitors by use of virtual screening. 2. The available chemical directory | Q46969984 | ||
| Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. | Q50105738 | ||
| A novel search engine for virtual screening of very large databases. | Q51241581 | ||
| Inhibition of tubercle bacilli in cultured human macrophages by chloroquine used alone and in combination with streptomycin, isoniazid, pyrazinamide, and two metabolites of vitamin D3 | Q28329787 | ||
| Comparative studies on the antirhinovirus activity and the mode of action of the rhinovirus capsid binding agents, chalcone amides | Q28330446 | ||
| Pradimicins A, B and C: new antifungal antibiotics. II. In vitro and in vivo biological activities | Q28330624 | ||
| Activity of minocycline against Toxoplasma gondii infection in mice | Q28332971 | ||
| Protective activity of tetracycline analogs against the cytopathic effect of the human immunodeficiency viruses in CEM cells | Q28334619 | ||
| Inhibition of HIV-1 RNA-dependent DNA polymerase and cellular DNA polymerases alpha, beta and gamma by phosphonoformic acid and other drugs | Q28338812 | ||
| In vivo antimalarial activity of the beta-carboline alkaloid manzamine A | Q28344290 | ||
| Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model | Q28344362 | ||
| Inhibitors of human immunodeficiency virus type 1 reverse transcriptase target distinct phases of early reverse transcription | Q28359887 | ||
| Susceptibility of Encephalitozoon cuniculi to several drugs in vitro | Q28367748 | ||
| The effect of artesunate combined with standard antimalarials against chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum in vitro | Q28370483 | ||
| Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine | Q28377023 | ||
| Inhibitors of human immunodeficiency virus integrase | Q28378683 | ||
| Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium | Q28378889 | ||
| Effects of albendazole, fumagillin, and TNP-470 on microsporidial replication in vitro | Q28379022 | ||
| Cyclosporine A-resistant human immunodeficiency virus type 1 mutants demonstrate that Gag encodes the functional target of cyclophilin A | Q28379060 | ||
| Chloroquine induces human mononuclear phagocytes to inhibit and kill Cryptococcus neoformans by a mechanism independent of iron deprivation | Q28379104 | ||
| Characterization of anti-Toxoplasma activity of SDZ 215-918, a cyclosporin derivative lacking immunosuppressive and peptidyl-prolyl-isomerase-inhibiting activity: possible role of a P glycoprotein in Toxoplasma physiology | Q28379120 | ||
| The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein | Q28379384 | ||
| Cyclosporin analogs inhibit in vitro growth of Cryptosporidium parvum | Q28379469 | ||
| Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo | Q29619108 | ||
| Virtual screening to enrich hit lists from high-throughput screening: a case study on small-molecule inhibitors of angiogenin. | Q31120824 | ||
| In silico prediction of drug toxicity | Q31165898 | ||
| Synthesis and anti-HIV activity of cosalane analogues incorporating nitrogen in the linker chain | Q31435601 | ||
| Virtual screening of chemical libraries | Q33209939 | ||
| Computational chemistry as an integral component of lead generation | Q33219757 | ||
| A clinical drug library screen identifies astemizole as an antimalarial agent | Q33248659 | ||
| Searching for new antimalarial therapeutics amongst known drugs | Q33252500 | ||
| Potential efficacy of fumagillin in intestinal microsporidiosis due to Enterocytozoon bieneusi in patients with HIV infection: results of a drug screening study. The French Microsporidiosis Study Group | Q33500799 | ||
| Durhamycin, a Pentaene Antifungal Antibiotic from Streptomyces durhamensis sp. n | Q33697131 | ||
| Identification, characterization, and gene expression profiling of endotoxin-induced myocarditis | Q33716185 | ||
| Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection | Q33915548 | ||
| Prediction of toxicity from chemical structure | Q33965477 | ||
| Screening for human ADME/Tox drug properties in drug discovery | Q34194499 | ||
| Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept. | Q34275256 | ||
| Structure of the aspartic protease plasmepsin 4 from the malarial parasite Plasmodium malariae bound to an allophenylnorstatine-based inhibitor | Q34498794 | ||
| Computer systems for the prediction of toxicity: an update | Q34581575 | ||
| Curcumin, a major component of food spice turmeric (Curcuma longa) inhibits aggregation and alters eicosanoid metabolism in human blood platelets | Q34722567 | ||
| Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, and Candida krusei | Q34735206 | ||
| Designing safer drugs: (Q)SAR-based identification of mutagens and carcinogens | Q35137601 | ||
| Progress in toxinformatics: the challenge of predicting acute toxicity | Q35137606 | ||
| SYSTEMIC FUNGAL INFECTIONS AMENABLE TO CHEMOTHERAPY | Q35396271 | ||
| The role of monoamines in the actions of established and "novel" antidepressant agents: a critical review | Q35908581 | ||
| The cost of antiretroviral drugs and influence on prescribing policies | Q36574085 | ||
| Cost-effectiveness of cotrimoxazole prophylaxis among persons with HIV in Uganda | Q38878419 | ||
| Neomycin B-arginine conjugate, a novel HIV-1 Tat antagonist: synthesis and anti-HIV activities | Q39182891 | ||
| In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria | Q39474756 | ||
| Hydroxychloroquine is much less active than chloroquine against chloroquine-resistant Plasmodium falciparum, in agreement with its physicochemical properties | Q39578722 | ||
| Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria | Q39658100 | ||
| Effects of amphotericin B on hepatitis B virus | Q39856205 | ||
| Antimycoplasmal activities of new quinolones, tetracyclines, and macrolides against Mycoplasma pneumoniae | Q39874994 | ||
| An appraisal of chloroquine | Q39990460 | ||
| Heparin-mimicking sulfonic acid polymers as multitarget inhibitors of human immunodeficiency virus type 1 Tat and gp120 proteins | Q40142273 | ||
| Fumagillin suppresses HIV-1 infection of macrophages through the inhibition of Vpr activity. | Q40288825 | ||
| Specific inhibition of hepatitis C virus replication by cyclosporin A. | Q40607971 | ||
| Inhibition of sandfly fever Sicilian virus (Phlebovirus) replication in vitro by antiviral compounds | Q40644135 | ||
| Role of G protein and protein kinase signalling in influenza virus budding in MDCK cells | Q40685591 | ||
| Out-of-pocket costs of HAART limit HIV treatment responses in Botswana's private sector | Q40799738 | ||
| Correlation of anti-HIV activity with anion spacing in a series of cosalane analogues with extended polycarboxylate pharmacophores. | Q40819335 | ||
| Antiviral effect of the combination of enviroxime and disoxaril on coxsackievirus B1 infection. | Q40854956 | ||
| Inhibition of vaccinia virus replication by cyclosporin A analogues correlates with their affinity for cellular cyclophilins. | Q41064293 | ||
| Inhibition of HIV-1 Tat-mediated transactivation by quinacrine and chloroquine | Q41168935 | ||
| Synergistic inhibitory effect of enviroxime and disoxaril on poliovirus type 1 replication. | Q41262732 | ||
| Cosalane analogues with enhanced potencies as inhibitors of HIV-1 protease and integrase | Q41370917 | ||
| Selective inhibition of human cytomegalovirus replication by naphthalenedisulfonic acid derivatives | Q41570828 | ||
| Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T cells and monocytes | Q41581307 | ||
| The polysulfonated compound suramin blocks adsorption and lateral difusion of herpes simplex virus type-1 in vero cells | Q41665306 | ||
| Angiogenesis inhibitors specific for methionine aminopeptidase 2 as drugs for malaria and leishmaniasis | Q41917973 | ||
| Suramin inhibits binding of the V3 region of HIV-1 envelope glycoprotein gp120 to galactosylceramide, the receptor for HIV-1 gp120 on human colon epithelial cells. | Q42282014 | ||
| Design, synthesis, and biological evaluation of cosalane, a novel anti-HIV agent which inhibits multiple features of virus reproduction | Q42282067 | ||
| Geometrically and conformationally restrained cinnamoyl compounds as inhibitors of HIV-1 integrase: synthesis, biological evaluation, and molecular modeling. | Q42539086 | ||
| Membrane fusion induced by the HIV type 1 fusion peptide: modulation by factors affecting glycoprotein 41 activity and potential anti-HIV compounds | Q42547467 | ||
| In-vitro activity of macrolides alone and in combination with artemisin, atovaquone, dapsone, minocycline or pyrimethamine against Cryptosporidium parvum | Q42552859 | ||
| Binding of cosalane--a novel highly lipophilic anti-HIV agent--to albumin and glycoprotein | Q43565704 | ||
| Comparison of in vitro activities of amphotericin, clotrimazole, econazole, miconazole, and nystatin against Fusarium oxysporum. | Q43644499 | ||
| Viral load, viral phenotype modification, zidovudine susceptibility and reverse transcriptase mutations during the first 6 months of zidovudine monotherapy in HIV-1-infected people | Q43700224 | ||
| Computer automated prediction of potential therapeutic and toxicity protein targets of bioactive compounds from Chinese medicinal plants | Q44029665 | ||
| Durhamycin A, a potent inhibitor of HIV Tat transactivation | Q44112337 | ||
| HIV-1 integrase inhibitory substances from Coleus parvifolius. | Q44388038 | ||
| Identification of potential HIV-1 targets of minocycline | Q44880657 | ||
| P433 | issue | 2 | |
| P921 | main subject | drug discovery | Q1418791 |
| drug screening | Q10505555 | ||
| P304 | page(s) | 62-71 | |
| P577 | publication date | 2008-01-10 | |
| P1433 | published in | Trends in Pharmacological Sciences | Q2451474 |
| P1476 | title | Novel paradigms for drug discovery: computational multitarget screening | |
| P478 | volume | 29 |
| Q44105963 | A Systematic Review of Computational Drug Discovery, Development, and Repurposing for Ebola Virus Disease Treatment. |
| Q28477458 | A network-based multi-target computational estimation scheme for anticoagulant activities of compounds |
| Q98513721 | An integrated drug repurposing strategy for the rapid identification of potential SARS-CoV-2 viral inhibitors |
| Q38989374 | Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview |
| Q108127160 | Artificial intelligence to deep learning: machine intelligence approach for drug discovery |
| Q24646505 | Biosynthesis and functions of mycothiol, the unique protective thiol of Actinobacteria |
| Q38141148 | Bridging the past and the future of virology: surface plasmon resonance as a powerful tool to investigate virus/host interactions. |
| Q28543019 | CANDO and the infinite drug discovery frontier |
| Q38789466 | Combating Ebola with Repurposed Therapeutics Using the CANDO Platform |
| Q90069138 | Computational chemoproteomics to understand the role of selected psychoactives in treating mental health indications |
| Q33687130 | Docking Small Molecules to Predicted Off-Targets of the Cancer Drug Erlotinib Leads to Inhibitors of Lung Cancer Cell Proliferation with Suitable In vitro Pharmacokinetic Properties |
| Q28305100 | Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs |
| Q47904178 | European Union conference on poverty-related diseases research |
| Q64951625 | Exploration of interaction scoring criteria in the CANDO platform. |
| Q35969861 | Exploring Polypharmacology in Drug Discovery and Repurposing Using the CANDO Platform. |
| Q36842185 | Gardiquimod: a Toll-like receptor-7 agonist that inhibits HIV type 1 infection of human macrophages and activated T cells |
| Q61451256 | Identifying Protein Features Responsible for Improved Drug Repurposing Accuracies Using the CANDO Platform: Implications for Drug Design |
| Q34908616 | In Silico Augmentation of the Drug Development Pipeline: Examples from the study of Acute Inflammation. |
| Q37707220 | In-silico approaches to multi-target drug discovery : computer aided multi-target drug design, multi-target virtual screening |
| Q37962486 | Metabolic network modeling and simulation for drug targeting and discovery |
| Q33966485 | Multi-target QSAR modelling in the analysis and design of HIV-HCV co-inhibitors: an in-silico study |
| Q35046420 | Multiple-targeting and conformational selection in the estrogen receptor: computation and experiment |
| Q36008720 | Mycobacterium Cytidylate Kinase Appears to Be an Undruggable Target |
| Q28297997 | Network pharmacology: the next paradigm in drug discovery |
| Q28534533 | Pathway-based screening strategy for multitarget inhibitors of diverse proteins in metabolic pathways |
| Q93202753 | Prospects of multitarget drug designing strategies by linking molecular docking and molecular dynamics to explore the protein-ligand recognition process |
| Q35844509 | Pyrazolo-Piperidines Exhibit Dual Inhibition of CCR5/CXCR4 HIV Entry and Reverse Transcriptase |
| Q47330584 | Quantitative structure-activity relationship of anti-HIV integrase and reverse transcriptase inhibitors using norm indexes |
| Q30420409 | Strategic protein target analysis for developing drugs to stop dental caries |
| Q37226478 | Synthetic genetic targeting of genome instability in cancer. |
| Q42378391 | Teriflunomide restores 5-azacytidine sensitivity via activation of pyrimidine salvage in 5-azacytidine-resistant leukemia cells |
| Q92403253 | The Promise and Challenge of Digital Biology |
| Q36280059 | The scoring bias in reverse docking and the score normalization strategy to improve success rate of target fishing. |
| Q28278411 | Virtual screening: an endless staircase? |
Search more.